ETCTN Trials by Disease/ Treatment Area: Leukemia

**Lymphocytic**
- R/R CD19+ precursor B-lymphoblastic leukemia
- CD3+ acute lymphoma, or poor-risk chronic subtypes of adult T-cell lymphoma/leukemia

**Myelogenous**
- AML with wild-type p53 (R/R or front line)
- AML associated with antecedent myeloproliferative disorder
- Mutated AML
- AML (front line therapy)

**Myelodysplastic syndrome**
- MDS or oligoblastic AML

**Hematologic malignancy**
- Hematologic malignancy, not otherwise stated

- **10030:** A Phase 1 Study of Blinatumomab in Combination with Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients with Poor Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
- **10335:** A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma

- **10026:** A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia

- **10246:** A Phase 1 Study of MLN4924 (Pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

- **10237:** A Phase 1 Study of MLN7243 (TAK243) for Either Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia Refractory to Hypomethylating Agents

- **10273:** A Phase I Study of M3814 in Combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia

- **10264:** The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

- **10075:** A Phase 1B Study of KRT232 (AMG232) in Combination with Decitabine in Acute Myeloid Leukemia

- **10367:** A Phase 1b Study with Expansion Cohort of Escalating Doses of KRT-232 (AMG 232) Administered in Combination with Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed Acute Myelogenous Leukemia (AML)

- **10147:** A Phase II Randomized Study of Topotecan/Carboplatin with or Without Veliparib in Advanced Myeloproliferative Disorders and Chronic Myelomonocytic Leukemia (CMMML)

- **10200:** A Phase Ib/Ii Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia

- **10317:** A Pilot Study of Nivolumab in Combination with Decitabine and Venetoclax in TP53-Mutated Acute Myeloid Leukemia

- **10122:** A Phase 1b/2 Study of Pinometostat in Combination with Standard Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with MLL Rearrangement

- **10300:** BLAST MRD AML: 1. A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy as Frontline Therapy in Patients with Acute Myeloid Leukemia

- **10334:** BLAST MRD AML: 2. A Randomized Phase 2 Study of Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine as First Line Therapy in Older Patients with Acute Myeloid Leukemia Who Are Ineligible or Who Refuse Intensive Chemotherapy

- **10099:** A Phase 1b Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients with Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure

- **10014:** A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies

**NOTE:** * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: June 15, 2020